{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:09:23Z","timestamp":1790838563149,"version":"4.1.0"},"reference-count":24,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hypereosinophilia (HE) has been defined as persistent eosinophilia &amp;gt;1.5 \u00d7 109\/L; it is broadly divided into primary HE (clonal or neoplastic; HEN), secondary\/reactive HE (HER), or HE of undetermined significance (HEUS) when no cause is identified. The use of myeloid next-generation sequencing (NGS) panels has led to the detection of several mutations in patients previously diagnosed with HEUS, reassigning some patients to the category of HEN, specifically the World Health Organization category of chronic eosinophilic leukemia, not otherwise specified (CEL, NOS). Here, we describe a novel somatic JAK1 pseudokinase domain mutation (R629_S632delinsSA) in a patient with HE that had initially been characterized as a variant of uncertain significance. We performed functional studies that demonstrated that this mutation results in growth factor independence of Ba\/F3 cells in vitro and activation of the JAK-STAT pathway. These effects were abrogated by the JAK1\/JAK2 inhibitor ruxolitinib. R629_S632delinsSA is the first known somatic mutation in JAK1 linked to a clonal eosinophilic neoplasm, and highlights the importance of the JAK-STAT pathway in eosinophil survival.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004237","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T19:17:28Z","timestamp":1631128648000},"page":"3581-3586","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":23,"title":["A novel activating <i>JAK1<\/i> mutation in chronic eosinophilic leukemia"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6500-350X","authenticated-orcid":false,"given":"William","family":"Shomali","sequence":"first","affiliation":[{"name":"Division of Hematology, Stanford Cancer Institute\/Stanford University School of Medicine, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7565-076X","authenticated-orcid":false,"given":"Alisa","family":"Damnernsawad","sequence":"additional","affiliation":[{"name":"Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR;"},{"name":"Department of Biology, Faculty of Science, Mahidol University, Bangkok, Thailand;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7297-6040","authenticated-orcid":false,"given":"Talent","family":"Theparee","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California at San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sampson","sequence":"additional","affiliation":[{"name":"Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinlan","family":"Morrow","sequence":"additional","affiliation":[{"name":"Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6965-8447","authenticated-orcid":false,"given":"Fei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Knight Cancer Institute, Oregon Health & Science University, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0428-0199","authenticated-orcid":false,"given":"Sebastian","family":"Fernandez-Pol","sequence":"additional","affiliation":[{"name":"Deparment of Pathology, Stanford University School of Medicine, Stanford, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2103-5144","authenticated-orcid":false,"given":"Richard","family":"Press","sequence":"additional","affiliation":[{"name":"Department of Pathology and Knight Cancer Institute, Oregon Health & Science University, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5380-303X","authenticated-orcid":false,"given":"James","family":"Zehnder","sequence":"additional","affiliation":[{"name":"Division of Hematology, Stanford Cancer Institute\/Stanford University School of Medicine, Stanford, CA;"},{"name":"Deparment of Pathology, Stanford University School of Medicine, Stanford, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Tyner","sequence":"additional","affiliation":[{"name":"Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, OR;"},{"name":"Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8253-6156","authenticated-orcid":false,"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[{"name":"Division of Hematology, Stanford Cancer Institute\/Stanford University School of Medicine, Stanford, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,9,21]]},"reference":[{"issue":"10","key":"2021092115291328500_B1","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/ajh.25617","article-title":"World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management","volume":"94","author":"Shomali","year":"2019","journal-title":"Am J Hematol."},{"key":"2021092115291328500_B2","first-page":"54","volume-title":"World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues.","author":"Bain","year":"2017","edition":"Revised 4th ed"},{"issue":"8","key":"2021092115291328500_B3","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2016.75","article-title":"Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified","volume":"29","author":"Wang","year":"2016","journal-title":"Mod Pathol."},{"issue":"2","key":"2021092115291328500_B4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41375-018-0342-3","article-title":"Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia","volume":"33","author":"Cross","year":"2019","journal-title":"Leukemia."},{"issue":"12","key":"2021092115291328500_B5","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1002\/eji.1830271256","article-title":"Anti-apoptotic signals of granulocyte-macrophage colony-stimulating factor are transduced via Jak2 tyrosine kinase in eosinophils","volume":"27","author":"Simon","year":"1997","journal-title":"Eur J Immunol."},{"issue":"9","key":"2021092115291328500_B6","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/ajh.24075","article-title":"KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance","volume":"90","author":"Schwaab","year":"2015","journal-title":"Am J Hematol."},{"issue":"26","key":"2021092115291328500_B7","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1182\/blood.2019001385","article-title":"JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera","volume":"134","author":"Patel","year":"2019","journal-title":"Blood."},{"issue":"7","key":"2021092115291328500_B8","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2015-06-654277","article-title":"Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome","volume":"127","author":"Walker","year":"2016","journal-title":"Blood."},{"key":"2021092115291328500_B9","first-page":"72","volume-title":"World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues.","author":"Bain","year":"2017","edition":"Revised 4th ed"},{"key":"2021092115291328500_B10","first-page":"PO.1700019","article-title":"Genomic profiling of T-cell neoplasms reveals frequent JAK1 and JAK3 mutations with clonal evasion from targeted therapies","volume":"2018","author":"Greenplate","year":"2018","journal-title":"JCO Precis Oncol."},{"issue":"23","key":"2021092115291328500_B11","doi-asserted-by":"crossref","first-page":"9414","DOI":"10.1073\/pnas.0811761106","article-title":"JAK mutations in high-risk childhood acute lymphoblastic leukemia","volume":"106","author":"Mullighan","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"issue":"8","key":"2021092115291328500_B12","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.3324\/haematol.2017.170266","article-title":"JAK1 somatic mutation in a myeloproliferative neoplasm","volume":"102","author":"Arulogun","year":"2017","journal-title":"Haematologica."},{"issue":"6","key":"2021092115291328500_B13","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.jaci.2016.12.957","article-title":"JAK1 gain-of-function causes an autosomal dominant immune dysregulatory and hypereosinophilic syndrome","volume":"139","author":"Del Bel","year":"2017","journal-title":"J Allergy Clin Immunol."},{"issue":"7326","key":"2021092115291328500_B14","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/nature09627","article-title":"COT drives resistance to RAF inhibition through MAP kinase pathway reactivation","volume":"468","author":"Johannessen","year":"2010","journal-title":"Nature."},{"issue":"1","key":"2021092115291328500_B15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/0008-5472.CAN-12-1906","article-title":"Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening","volume":"73","author":"Tyner","year":"2013","journal-title":"Cancer Res."},{"issue":"14","key":"2021092115291328500_B16","doi-asserted-by":"crossref","first-page":"22606","DOI":"10.18632\/oncotarget.15146","article-title":"Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors","volume":"8","author":"Pietarinen","year":"2017","journal-title":"Oncotarget."},{"issue":"4","key":"2021092115291328500_B17","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1084\/jem.20072182","article-title":"Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia","volume":"205","author":"Flex","year":"2008","journal-title":"J Exp Med."},{"issue":"19","key":"2021092115291328500_B18","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N Engl J Med."},{"issue":"8","key":"2021092115291328500_B19","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20090693","article-title":"An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia","volume":"206","author":"Plo","year":"2009","journal-title":"J Exp Med."},{"issue":"8","key":"2021092115291328500_B20","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1158\/1078-0432.CCR-13-0279","article-title":"Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors","volume":"20","author":"Meyer","year":"2014","journal-title":"Clin Cancer Res."},{"issue":"D1","key":"2021092115291328500_B21","doi-asserted-by":"crossref","first-page":"D506","DOI":"10.1093\/nar\/gky1049","article-title":"UniProt: a worldwide hub of protein knowledge","volume":"47","author":"UniProt Consortium","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"2021092115291328500_B22","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/nsmb.2673","article-title":"Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases","volume":"20","author":"Toms","year":"2013","journal-title":"Nat Struct Mol Biol."},{"key":"2021092115291328500_B23"},{"key":"2021092115291328500_B24"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/18\/3581\/1823186\/advancesadv2021004237.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/18\/3581\/1823186\/advancesadv2021004237.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,21]],"date-time":"2021-09-21T15:46:59Z","timestamp":1632239219000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/18\/3581\/476811\/A-novel-activating-JAK1-mutation-in-chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":24,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021,9,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004237","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,8]]}}}